Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Name: Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Published: 2021
License: Public Domain

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

hepatocellular-carcinoma immunotherapy nivolumab

hepatocellular carcinoma, relatlimab, nivolumab, immunotherapy, anti pd-1, anti - lag-3, resectable hepatocellular cancer, potentially resectable hepatocellular cancer, hepatocellular cancer (hcc), interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Related documents